PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Schmieder, R.S.* ; Krefting, J.* ; Ates, S.* ; Schlieben, L.D. ; Arens, S.* ; Kordonouri, O.* ; Sander, M.* ; Holdenrieder, S.* ; Mall, V.* ; Meitinger, T.* ; von Scheidt, M.* ; Koenig, W.* ; Leipold, G.* ; Prokisch, H. ; Schunkert, H.* ; Sanin, V.*

Clinical scores fail to sufficiently identify children with Familial Hypercholesterolemia.

Eur. J. Prev. Cardiol., DOI: 10.1093/eurjpc/zwaf301 (2025)
Verlagsversion Forschungsdaten DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
AIM: The study aimed to assess the effectiveness of three clinical diagnostic criteria (Simon Broome, MEDPED, and guideline-derived) in identifying children with familial hypercholesterolemia (FH) compared to genetic testing. The evaluation involved 1337 children with elevated LDL-C levels, focusing on the sensitivity and specificity of these clinical scores in detecting genetically confirmed FH cases. METHODS: Clinical data were gathered by a self-reporting questionnaire. Clinical FH was defined in accordance with the tested FH score. Genetically confirmed heterozygous FH (HeFH) was defined by a (likely) pathogenic variant. RESULTS: Of 1337 children undergoing genetic analysis, 211 showed a pathogenic FH mutation. Applying SB, MP and GL-EAS criteria resulted in 210/1337, 125/1337 and 112/835 children being categorized to have FH clinically. The sensitivity of the clinical scores ranged from 0.44-0.54 with a positive predictive value (PPV) of 0.51-0.79. The specificity was 0.91-0.97 with a negative predictive value (NPV) of 0.89-0.91. Similar results were observed for the three clinical scores regarding sensitivity, specificity, PPV and NPV in subgroup analyses defined by gender, age (<10 years vs ≥10 years), or weight (≥90th BMI-percentile vs <90th BMI-percentile). CONCLUSION: Clinical FH scores offer a high degree of specificity for FH diagnosis in children, but at the expense of low sensitivity. Specifically, half of the mutation-positive children in this study would have been missed for early diagnosis and preventive treatment. Given the widespread availability of affordable genetic testing such analysis should be performed at a lower threshold than that indicated by these clinical scores.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Altmetric
7.500
0.000
1
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Familial Hypercholesterolemia ; Clinical Scores ; Genetic Testing ; Prevention ; Screening; Diagnosis; Population; Statins; Risk; Care
Sprache englisch
Veröffentlichungsjahr 2025
HGF-Berichtsjahr 2025
ISSN (print) / ISBN 2047-4873
e-ISSN 2047-4881
Zeitschrift European Journal of Preventive Cardiology
Verlag Sage
Verlagsort Great Clarendon St, Oxford Ox2 6dp, England
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Neurogenomics (ING)
POF Topic(s) 30205 - Bioengineering and Digital Health
Forschungsfeld(er) Genetics and Epidemiology
PSP-Element(e) G-503292-001
Förderungen
Bayerisches Staatsministerium fur Gesundheit, Pflege und Prevention (Bavarian State Ministry of Health, Care and Prevention) StMGP
DOI 10.1093/eurjpc/zwaf301
WOS ID 001541568100001
PubMed ID 40632909
Erfassungsdatum 2025-07-18
[➜Korrektur melden]